Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AU-101
- Development stage
- Unknown
- Lead developer
- Aura Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Suprachoroidal
01
Overview
AU-101 is a drug candidate developed by Aura Biosciences for the treatment of ocular melanoma. It is identified as belantamab, which is an antibody-drug conjugate (ADC). ADCs are designed to deliver a cytotoxic agent directly to cancer cells by linking it to a monoclonal antibody that targets a specific protein on the cancer cell surface. In the context of ocular melanoma, AU-101 is delivered using Clearside Biomedical's proprietary SCS Microinjector, enabling precise suprachoroidal tumor targeting. Belantamab mafodotin, a related ADC, is known to target B-cell maturation antigen (BCMA) and utilizes monomethyl auristatin F (MMAF) as its cytotoxic payload.
- Other names
- belantamab
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on AU-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AU-101.